Vertex to Acquire ViaCyte for ~$320M and Deliver Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes
Shots:
- Vertex to acquire ViaCyte for $320M in cash. The transaction is expected to close in 2022
- ViaCyte brings tools, technologies & complementary assets incl. additional human stem cell lines, intellectual property around stem cell differentiation, and GMP manufacturing facilities to accelerate the development of VX-880 & reduce the burden of patients with T1D globally
- In an ongoing P-I/II study, VX-880, an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy showed PoC with very encouraging safety and efficacy results for T1D. Under the ViaCyte partnership with CRISPR Therapeutics, the acquisition also gives access to new hypoimmune stem cell assets
Ref: Businesswire| Image: ViaCyte
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
